Age is a major risk factor for rheumatoid arthritis (RA), yet we understand little of the role ageing processes play in RA pathogenesis. Why this matters is that if ageing processes are a driver for RA, then improved understanding of the mechanisms involved may reveal innovative approaches to prevention or early treatment of this disease.
Project LeadJ Lord
The group hypothesise that environmental factors such as smoking and genetic predisposition can cause premature ageing leading to an aged epigenome signature, driving immunesenescence and RA pathogenesis. DNA methylation at 350 speciﬁc sites, termed the epigenetic clock, has been identiﬁed as an indicator of biological age. The study will analyse existing data from patients with established RA and generate new data from very early RA cohorts across Europe to determine if the DNA methylation signature shows advanced ageing in RA patients and if this occurs in the earliest stages of the disease. Also immune phenotype at the various stages of disease development will be assessed to see if this occurs early or is a consequence of disease.
M1 (mth 1): Kick off workshop to organise sample collection, re-distribution to analysis sites, standard operating procedures for sample collection, storage and shipping.
M2 (mth 3): PRPgroup established and first meeting held to establish role and working method.
M3 (mth 12): Analysis of existing DNAm data complete and manuscript submitted. 2ndworkshop held.
M4 (mth 24): Collection of new samples & distribution to analysis sites complete. 3rdworkshop held.
M5 (mth 30): Immune phenotyping complete and manuscript prepared.
M6 (mth 36): DNAm analysis and modelling complete and manuscript prepared. Final workshop held.
M7 (mth 36): Public dissemination strategy finalised with PRP.Budget:
The project will include patient representatives at each site to support the writing of the patient information sheets and to help communicate the ﬁndings of the project. Close work with a patient group in Birmingham.